TMEM238: A Transmembrane Protein for Drug Targets and Biomarkers

Target Name: TMEM238

NCBI ID: G388564

TMEM238

Other Name(s): transmembrane protein 238 | Transmembrane protein 238 | TM238_HUMAN

TMEM238: A Transmembrane Protein for Drug Targets and Biomarkers

TMEM238 (Transmembrane Protein 238) is a protein that is expressed in various cell types, including human epithelial tissues, breast epithelial cells, and neuroblasts. It plays a crucial role in the development, maintenance, and regulation of cell structure and function. TMEM238 has also been identified as a potential drug target and biomarker. In this article, we will explore the molecular mechanisms of TMEM238, its potential as a drug target, and its role as a biomarker in various diseases.

Molecular Mechanisms of TMEM238

TMEM238 is a transmembrane protein that is expressed in the cytoplasm and nuclear envelope of epithelial cells. It consists of a cytoplasmic tail, a transmembrane domain, and an N-terminus that is involved in protein-protein interactions. TMEM238 is a member of the TSP (Transmembrane Protein) family, which includes various proteins that play a vital role in the regulation of cell signaling pathways, including the T-cell signaling pathway.

TMEM238 is involved in several cellular processes, including cell adhesion, migration, and invasion. It is a critical regulator of the cytoskeleton and has been shown to play a role in the regulation of cell shape and the formation of tight junctions. TMEM238 has also been shown to be involved in the regulation of cell growth, apoptosis, and angiogenesis.

In addition to its role in cell signaling pathways, TMEM238 has also been identified as a potential drug target. Its expression has been shown to be downregulated in various types of cancer, including breast cancer (5), and its overexpression has been shown to promote the growth and survival of cancer cells. This suggests that TMEM238 may be a promising target for cancer therapies.

Potential as a Drug Target

Several studies have shown that TMEM238 can be targeted by small molecules, including inhibitors of tyrosine kinase (TK) signaling pathways (7), which are involved in cell signaling pathways, including the T-cell signaling pathway. These inhibitors have been shown to reduce the expression of TMEM238 and inhibit its function. Additionally, TMEM238 has been shown to interact with several protein partners, including the transcription factor, p53. Therefore, targeting TMEM238 and its protein partners may be an effective way to inhibit the functions of cancer cells.

Role as a Biomarker

TMEM238 has also been identified as a potential biomarker for several diseases, including cancer. Its expression has been shown to be downregulated in various types of cancer, including breast cancer (5), and its overexpression has been shown to promote the growth and survival of cancer cells. Therefore, TMEM238 may be a useful biomarker for the diagnosis and prognosis of cancer.

In addition to its potential as a drug target, TMEM238 has also been shown to play a role in the regulation of cell signaling pathways. Its expression has been shown to be involved in the regulation of several cellular processes, including cell adhesion, migration, and invasion. Therefore, TMEM238 may also be a useful biomarker for the assessment of therapeutic interventions in cancer and other diseases.

Conclusion

In conclusion, TMEM238 is a transmembrane protein that is involved in several cellular processes and has been identified as a potential drug target and biomarker. Its expression is downregulated in various types of cancer and its overexpression has been shown to promote the growth and survival of cancer cells. Further research is needed to fully understand the role of TMEM238 in cellular signaling pathways and its potential as a drug

Protein Name: Transmembrane Protein 238

The "TMEM238 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about TMEM238 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets